Since TP53 is the most mutated gene in cancer, we checked the CDKN1A transcript level using CDK1NA (P21) specific primer (Supplementary Table S3) as mutations in CDKN1A are less frequent and CDKN1A is a direct target and a downstream effector for p53. This evidence concerns the gene TP53 and cancer.